Chimeric antigen receptor- (CAR-) T cell therapy is one of the most recent innovative immunotherapies and is rapidly evolving. Like other technologies, CAR-T cell therapy has undergone a long development process, and persistent explorations of the actions of the intracellular signaling domain and make several improvements have led to the superior efficacy when anti-CD19 CAR-T cell treatments in B cell cancers. At present, CAR-T cell therapy is developing rapidly, and many clinical trials have been established on a global scale, which has great commercial potential. This review mainly describes the toxicity of CAR-T cell therapy and the challenges of CAR-T cells in the treatment of solid tumors, and looks forward to future development and opportunities for immunotherapy and reviews major breakthroughs in CAR-T cell therapy.
Mendeley helps you to discover research relevant for your work.
CITATION STYLE
Zhang, Q., Ping, J., Huang, Z., Zhang, X., Zhou, J., Wang, G., … Ma, J. (2020). CAR-T Cell Therapy in Cancer: Tribulations and Road Ahead. Journal of Immunology Research. Hindawi Limited. https://doi.org/10.1155/2020/1924379